anti-Nipah_275
| anti-Nipah_ID | anti-Nipah_275 |
| anti-Nipah Drug | Poly(I)-poly(C12U) |
| Nipah virus strain | NiV (Malaysia-1999) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | In-vivo |
| Models used to test anti-Nipah activity | Hamsters |
| Mode of infection to test anti-Nipah activity | Intraperitoneal |
| Viral titer to test anti-Nipah activity | 35 LD50 |
| Mode of Drug delivery for anti-Nipah activity | Intraperitoneal |
| Time of Drug delivery for anti-Nipah activity | Post Infection |
| Duration of Drug delivery for anti-Nipah activity | 10 days |
| Drug concentration used to test anti-Nipah activity | 3 mg/kg/day |
| Assays used to test anti-Nipah activity | Survival assay |
| anti-Nipah activity | Increase [Percentage survival (NA NA)] |
| Survival rate of anti-Nipah compounds | 80 |
| References | Georges-Courbot MC, Contamin H, Faure C, Loth P, Baize S, Leyssen P, Neyts J, Deubel V. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob Agents Chemother. 2006 May;50(5):1768-72. |
| Comments | Both ribavirin and 6-aza-uridine were able to delay but not prevent Nipah virus-induced mortality. Poly(I)-poly(C(12)U), at 3 mg/kg of body weight daily from the day of infection to 10 days postinfection, prevented mortality in 5 of 6 infected animals. |